QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
by Betsy Haberl Dr. Stacy Loeb met Dr. William J. Catalona when she was a student at Northwestern University’s Feinberg School of Medicine. Their relationship began as mentor and mentee, but now they are colleagues in the field of medical…
Researchers analyzed 16 studies including more than one million people and found that drinking more coffee was correlated with lower risks of developing prostate cancer. For each additional cup of coffee, there was a nearly 1% decrease in the risk…
Claims that omega-3 fatty acid supplements, including fish oil supplements, are an easy way to reduce the risks of heart disease have spurred their popularity. However, recent research does not support the claim that taking omega-3 supplements is an effective…
by Wayne Lewis Health disparities occur in prostate cancer: risk for the disease is about 75% higher and is more than twice as deadly in Black men compared with white men. Yet white men are often overrepresented as research participants,…
Adam B. Murphy, MD, MBA, MSCI is Assistant Professor in the Department of Urology & Preventive Medicine at Northwestern University. He is Principal Investigator of a new study seeking to develop a genetic panel specifically to predict lethal prostate cancer…
A new drug approved by the Food and Drug Administration (FDA) is expected to immediately affect the treatment of some men with prostate cancer. In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at…
Early in his career, Dr. Catalona cared for patients who were suffering and dying from metastatic prostate cancer, when disease was caught too late to be cured. After this experience, he was moved to dedicate his research to the early…
Even after apparently successful treatment, prostate cancer can unfortunately return, sometimes growing and spreading rapidly many years after the initial diagnosis. This occurs in prostate cancer when cancer cells leave the prostate early in the cancer’s development and hide in…
The FDA approved a new, more precise method of finding even the tiniest amounts of metastatic prostate cancer spread throughout in the body. The test, called a PSMA-PET scan, will make it easier to diagnose—and treat—metastatic prostate cancer sooner. The…
Previous research has reported on the impact of the U.S. Preventive Services Task Force recommendations against PSA screening for prostate cancer in 2008 for older men and in 2012 for all men. The rates of localized prostate cancer decreased, while…
